



## ASX ANNOUNCEMENT

### Results of Annual General Meeting & Special General Meeting

**Sydney, 29 November 2017: Actinogen Medical (ASX: ACW)** advises that the Company held its Annual General Meeting and Special General Meeting today, 29 November 2017 commencing at 10.30 am (AEDT).

The resolutions voted were in accordance with the Notice of Annual General Meeting and Notice of Special General Meeting previously advised to the Australian Securities Exchange.

Further information, required by Section 251AA(2) of the Corporations Act 2001 (Cth), is attached.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is positioned above the typed name and title.

**Peter Webse**  
Company Secretary

### About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

### About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 $\beta$ -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**



ANNUAL GENERAL MEETING  
Wednesday, 29 November, 2017

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 ADOPTION OF REMUNERATION REPORT	190,871,453	655,405	1,909,608	175,012	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
2 APPROVAL OF 10% PLACEMENT FACILITY	218,435,818	524,315	19,379,817	489,500	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
3 RE-ELECTION OF DIRECTOR DR JASON LOVERIDGE	219,228,947	79,501	19,316,002	205,000	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
4 RE-ELECTION OF DIRECTOR DR GEOFFREY BROOKE	219,228,947	79,501	19,316,002	205,000	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
5 RATIFICATION OF GRANT OF UNLISTED OPTIONS TO DR GEOFFREY BROOKE	189,889,346	1,243,078	1,979,608	499,446	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
6 RATIFICATION OF GRANT OF ADVISOR OPTIONS TO CONSULTANTS	217,703,056	1,038,577	19,648,502	439,315	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands
7 CANCELLATION OF UNVESTED LOAN SHARES	218,877,252	208,000	19,654,817	89,381	Passed on a show of hands	Passed on a show of hands	Passed on a show of hands

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item

**Results of Special General Meeting**

29 November 2017

RESOLUTION		Proxy and Direct Votes Lodged as at Proxy Close				Number of Votes Cast in Person or by Proxy on a Poll		
		For	Against	Discretionary	Abstain	For	Against	Abstain
1	Cancellation of Unvested Loan Shares	5,000,000	-	-	-	Passed on a Show of Hands	Passed on a Show of Hands	Passed on a Show of Hands

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the above statistics are provided in respect of each resolution on the Notice of Meeting

Note - Abstention votes are not counted in computing the required majority on a poll